Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received separate clinical trial approvals from the National Medical Products Administration (NMPA) for two of its drug candidates: HRS-5346 tablets and SHR-9539 injection.
HRS-5346, a small molecule drug developed in-house, is now approved for assessment in lipoprotein disorders. Preclinical data has indicated that HRS-5346 improves the body’s lipoprotein disorder with a favorable safety profile. Currently, there is no similar product approved for marketing globally.
On the other hand, SHR-9539 is a Category 1 biologic designed to induce and activate T cells, which then provide targeted killing effects on multiple myeloma (MM) cells. With this approval, SHR-9539 can now proceed to clinical trials for the treatment of MM, and like HRS-5346, there are no similar products approved either domestically or internationally.- Flcube.com
